688576.SHG Chongqing Xishan Science&Technology Co. Ltd. A
- Market cap
- CNY 2.43B
- P/E
- -
- P/B
- 1.37x
- ROE
- -3.0%
- Dividend yield
- 1.86%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688576.SHG undervalued?
Graham numberThe Graham number of Chongqing Xishan Science&Technology Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chongqing Xishan Science&Technology Co. Ltd. A fundamental analysis
No fundamental analysis for Chongqing Xishan Science&Technology Co. Ltd. A yet.
Chongqing Xishan Science&Technology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chongqing Xishan Science&Technology Co. Ltd. A
Chongqing Xishan Science & Technology Co., Ltd. engages in the research and development, manufacturing, sale, and service of digital minimally invasive surgical equipment and medical consumables in China and internationally. The company offers powered surgical instruments, such as micromotor, handpiece, attachment, shaver, bur, saw blade, and perforator; vacuum-assisted breast biopsy, including control module, handpiece, probe, and canister. It also provides UHD endocsopy sy…
Full company profileChongqing Xishan Science&Technology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chongqing Xishan Science&Technology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 209M | 262M | 361M | 336M | 342M | 239M |
| Gross Profit | 146M | 180M | 249M | 237M | 218M | 144M |
| Operating Income | 55.3M | 70.1M | 109M | 75.3M | 40.3M | -55.5M |
| EBITDA | - | 83.8M | 138M | 125M | 66.0M | -55.5M |
| Net Income | 61.4M | 75.4M | 117M | 98.7M | 51.9M | -50.9M |
| EPS | 1.55 | 1.90 | 2.21 | 1.99 | 0.77 | -0.75 |
| Balance Sheet | ||||||
| Total Assets | 404M | 523M | 2.32B | 1.93B | 1.90B | 1.81B |
| Total Liabilities | 77.9M | 116M | 157M | 161M | 171M | 123M |
| Shareholders' Equity | 326M | 406M | 2.16B | 1.77B | 1.73B | 1.68B |
| Cash & Short-term Investments | 304M | 333M | 712M | 558M | 289M | 257M |
| Cash Flow | ||||||
| Operating Cash Flow | 55.9M | 79.1M | 68.1M | 39.5M | 60.0M | - |
| Capital Expenditure | 14.2M | 49.2M | 104M | 158M | 96.0M | 62.5M |
| Free Cash Flow | 41.7M | 29.9M | -35.6M | -118M | -36.0M | -167M |
| Ratios | ||||||
| ROE | 18.9% | 18.5% | 5.4% | 5.6% | 3.0% | -3.0% |
| ROA | 15.2% | 14.4% | 5.1% | 5.1% | 2.7% | -2.8% |
| Net Profit Margin | 29.4% | 28.7% | 32.5% | 29.3% | 15.2% | -21.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Chongqing Xishan Science&Technology Co. Ltd. A dividends
- Dividend yield
- 1.86%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 87.1%
- Ex-dividend date
- Jun 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 45.2M | 0.67 | 87.1% |
| 2024 | CNY 48.9M | 0.99 | 49.5% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | CNY 29.7K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.49:1 on Jun 23, 2026.
Who owns Chongqing Xishan Science&Technology Co. Ltd. A
- Insiders 62.25%
- Institutions 5.42%
- Public & others 32.34%
- Shares outstanding 67.6M
- Free float 39.7M
Chongqing Xishan Science&Technology Co. Ltd. A company profile
- Company name
- Chongqing Xishan Science&Technology Co. Ltd. A
- Ticker
- 688576.SHG
- ISIN
- CNE100007820
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 695
- Fiscal year end
- December
- Address
- No. 2, Kangzhu Road, Chongqing, China, 401123
- Phone
- 86 23 6321 1087
- Website
- xishantech.com.cn
About Chongqing Xishan Science&Technology Co. Ltd. A
Chongqing Xishan Science & Technology Co., Ltd. engages in the research and development, manufacturing, sale, and service of digital minimally invasive surgical equipment and medical consumables in China and internationally. The company offers powered surgical instruments, such as micromotor, handpiece, attachment, shaver, bur, saw blade, and perforator; vacuum-assisted breast biopsy, including control module, handpiece, probe, and canister. It also provides UHD endocsopy systems comprising camera control unit, camera head, light source unit, LCD monitor, transforaminal endoscope, arthroscope, laparoscope, and trolley; ultrasonic bone scalpel systems; RF/HF electrosurgical unit and surgical electrode; and plasma electrosurgical unit and plasma surgical electrode. The company was founded in 1999 and is headquartered in Chongqing, China.
Chongqing Xishan Science&Technology Co. Ltd. A management
6- Mr. Yijun GuoChairman of the Board & General Manager · born 1965
- Ms. Xue BaiFinancial Director, Secretary of the Board & Director · born 1985
- Mr. Xi LiangDeputy GM & Director · born 1971
- Ms. Changying WangDeputy GM & Director · born 1981
- Mr. Zhu ChenDeputy General Manager · born 1982
- Ms. Airong HeHuman Resources Director · born 1981